UBE2B Activators
UBE2B Activators are a diverse group of compounds that indirectly enhance the functional activity of UBE2B through various mechanisms impacting the ubiquitin-proteasome system and related cellular pathways. Proteasome inhibitors like MG132, Bortezomib (also known as Velcade), and Lactacystin play a crucial role in this process. These inhibitors lead to the accumulation of ubiquitinated proteins within the cell, thereby creating a higher demand for UBE2B's ubiquitin-conjugating activity. Similarly, Leupeptin and Withaferin A, by inhibiting protease activity and inducing proteasomal inhibition respectively, contribute to an increased requirement for UBE2B's function in maintaining protein homeostasis. In a similar vein, PYR-41, by inhibiting the upstream ubiquitin-activating enzyme E1, disrupts the initial steps of ubiquitination, resulting in a compensatory increase in UBE2B-mediated ubiquitination activities.
Additionally, compounds such as Thalidomide, MLN4924, and Tunicamycin indirectly modulate UBE2B activity through their effects on related cellular pathways. Thalidomide's impact on the ubiquitin-proteasome system, MLN4924's inhibition of the NEDD8-activating enzyme, and Tunicamycin's induction of ER stress all lead to an increased reliance on UBE2B for the ubiquitination of proteins. Furthermore, Chloroquine and Oligomycin enhance UBE2B activity by interfering with lysosomal function and ATP synthesis, respectively. These disruptions cause cellular stress, further shifting the cellular reliance towards the ubiquitin-proteasome pathway where UBE2B is a key component. Collectively, these UBE2B Activators, through their targeted effects on protein degradation pathways and cellular stress responses, facilitate the enhancement of UBE2B mediated functions crucial for maintaining cellular protein balance.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132, a proteasome inhibitor, enhances UBE2B activity by preventing the degradation of proteins involved in the ubiquitin-proteasome pathway, indirectly increasing the substrate availability for UBE2B. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41, a ubiquitin-activating enzyme E1 inhibitor, indirectly enhances UBE2B activity by disrupting upstream ubiquitination processes, leading to an increased demand for UBE2B-mediated ubiquitination to maintain protein homeostasis. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, another proteasome inhibitor, indirectly activates UBE2B by accumulating ubiquitinated proteins, thereby increasing the need for UBE2B's ubiquitin-conjugating activity. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide, through its modulatory effects on the ubiquitin-proteasome system, indirectly enhances UBE2B activity by altering the protein degradation landscape, which can lead to increased UBE2B-mediated ubiquitination. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924, a NEDD8-activating enzyme inhibitor, indirectly activates UBE2B by disrupting neddylation processes, which affects the ubiquitination system, thereby increasing the functional demand on UBE2B. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $72.00 $145.00 $265.00 $489.00 $1399.00 $99.00 | 19 | |
Leupeptin, a protease inhibitor, indirectly enhances UBE2B activity by inhibiting the breakdown of proteins, including those involved in the ubiquitin-proteasome pathway, thus potentially increasing the substrates available for UBE2B. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin, a specific proteasome inhibitor, indirectly activates UBE2B by stabilizing proteins targeted for degradation, increasing the need for UBE2B's ubiquitin-conjugating activity in the cell. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine, known for its lysosomal inhibitory effects, can indirectly enhance UBE2B activity by affecting the autophagy-lysosome pathway, thereby shifting cellular reliance towards the ubiquitin-proteasome system involving UBE2B. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin, an inhibitor of N-linked glycosylation, indirectly activates UBE2B by causing ER stress and upregulating the ubiquitin-proteasome pathway, in which UBE2B is a key player. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $175.00 $600.00 $1179.00 $5100.00 $9180.00 | 26 | |
Oligomycin, an inhibitor of ATP synthase, indirectly enhances UBE2B activity by causing cellular stress, which often leads to an increased dependence on the ubiquitin-proteasome pathway where UBE2B functions. | ||||||